Form 4: BioXcel Therapeutics Director Peter Mueller Acquires Stock Options

Director Peter Mueller acquired 17,000 stock options in BioXcel Therapeutics, Inc. on June 10, 2024.

Summary

• Peter Mueller, a director of BioXcel Therapeutics, Inc., acquired 17,000 stock options on June 10, 2024.
• The options have an exercise price of $1.44.
• The options vest on the earlier of the first anniversary of the grant date or the day before the next annual meeting of the Issuer's stockholders after the grant date, contingent on continued service as a non-employee director.
• The options expire on June 10, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be interpreted as a sign of confidence, but it doesn't provide enough information to strongly skew positive or negative.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by a director as a positive signal, potentially influencing the stock price.

Key Dates

Keywords

BioXcel Therapeutics, Stock Options, Director, Peter Mueller, BTAI, Acquisition, Form 4